This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Jazz Pharmaceuticals plc
11/2/2026
Ladies and gentlemen, thank you for standing by. Welcome to Jazz Pharmaceuticals' 2026 third quarter earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star one one on your telephone. You will then hear an automated message of us and your hand is raised. And we do ask you please to limit to one question. and to withdraw your question please press star 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to John Bluth, Head of Investor Relations. Please go ahead.
Thank you and good afternoon everyone. Today Jazz Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the investor section of our website along with the press release and quarterly report on Form 10-Q for the quarter ended September 30, 2026. On the call today are Renee Gala, President and Chief Executive Officer, Sam Pearce, Chief Commercial Officer, Robbie Iannone, Global Head of R&D and Chief Medical Officer, and Phil Johnson, Chief Financial Officer. On slide two, I'd like to remind you that today's webcast includes forward-looking statements such as those related to our future financial and operating results growth potential and anticipated development regulatory and commercial milestones which involve risks and uncertainties that could cause actual events performance and results to differ materially from those contained in these forward-looking statements. We encourage you to review these risks and uncertainties described in today's press release and under the caption risk factors in our annual report on form 10k for the fiscal year ended December 31, 2025 and quarterly report on form 10q for the quarter ended September 30, 2026. We undertake no duty or obligation to update our forward-looking statements. Furthermore, we will discuss non-GAAP financial measures on this webcast. Descriptions of these non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release and the slide presentation available on the Investors section of our website. I'll now turn the call over to Renee.
Thank you, John. Good afternoon, everyone, and thank you for joining us today. Our third quarter results demonstrate the progress we are making as we build a more innovative and diversified JAZ. We delivered record revenues of $1.24 billion, an increase of 10% year over year, while advancing several important drivers of our future growth. Most notably, the FDA approval and launch of Zyhera and first line HER2 positive metastatic GEA was a defining milestone for JAZ. Establishing an important new source of growth and marking the beginning of what we believe could be a much broader opportunity across HER2 expressing cancers. And as you'll hear from Sam, the launch is off to a fantastic start. Longer term data presented at ESMO further strengthen our conviction in Zyhera and we continue to see peak sales potential of 3 to 5 billion dollars. Our commercial portfolio is performing well, with multiple products contributing to our growth. Oncology revenues grew 35% year-over-year, driven by the launches of Medeso and Zepselka in the first-line maintenance setting, while sustained demand for Zywave continued to underscore its durability and differentiation. Given our third quarter performance, we have increased our 2026 revenue guidance, as Phil will outline later in the call. Our sustained performance and disciplined approach to capital allocation place us in an excellent position to continue investing in our business today while further building new sources of growth for the future. One important example of how we are investing for the future is our acquisition of Actio Biosciences, which we completed during the quarter. This acquisition brings ABS 1230 into the Jazz pipeline and builds on our leadership in rare epilepsy. ABS 1230 is a clinical stage novel small molecule precision therapy designed to selectively inhibit the KCNT1 ion channel. In early proof of concept trials, ABS 1230 demonstrated meaningful seizure reductions that provide a high degree of confidence in the mechanism and molecule. We look forward to presenting initial patient data at a medical meeting this quarter, which we believe will generate shared excitement for the program. As outlined on slide five, the ACTIO acquisition illustrates the type of rare disease opportunities we are seeking. Highly differentiated assets in areas of significant unmet medical need where we believe JAS can create meaningful value. and the cash flow generated by our commercial portfolio gives us the flexibility to pursue additional opportunities with the same disciplined approach. Before turning the call over to Sam, I want to take a moment to recognize the tremendous contributions she has made to Jazz. Under her leadership, our commercial teams have achieved major milestones, including propelling Epidiolex to Blockbuster status, executing key oncology launches and further establishing our leadership in sleep medicine. Equally important, Sam has built a highly capable commercial leadership team that is driving our performance today and is well positioned to carry it forward. She will remain with Jazz through the appointment of her successor to support a seamless transition. Sam, we are deeply grateful for your leadership and contributions and we wish you a wonderful well-deserved retirement. With that, I'll turn the call over to Sam to review our commercial performance.
You're reading a preview of the JAZZ Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing